CN Bio PhysioMimix Organ-on-a-Chip data supports Inipharm’s INI-822 for metabolic liver disease treatment now in clinical testing Post author: Post published:December 4, 2023 Post category:uncategorized CN Bio today announced its PhysioMimix® assay for Non-alcoholic steatohepatitis (NASH). You Might Also Like Watch: She’s at high risk of breast cancer. She moved, and her screening costs soared. July 10, 2025 Artificial intelligence enhances radiologists’ accuracy in breast cancer detection July 8, 2025 Study reveals unique evolution of knee bone in humans linked to upright walking September 11, 2024